Overview

A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.

Status:
Terminated

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters. Furthermore the relation between the blood concentrations and the blood clotting effect will be investigated. Safety will be investigated as well. The objective of these investigations is to determine the optimal dose of DPOC-4088 that, achieves a relevant increase in a specific blood clotting parameter (the ecarin clotting time) without safety concerns.

Phase:

Phase 1

Details

Lead Sponsor:

Diakron Pharmaceuticals

Collaborators:

Drug Research Unit Ghent, Ghent, Belgium
Kinesis Pharma B.V.
Kinesis Pharma BV, Breda, the Netherlands